HIV i-Base

HIV i-Base is a treatment activist group, HIV-positive led and committed to providing timely HIV treatment information both to positive people and to health care professionals.

This includes technical publications like HIV Treatment Bulletin (HTB) and ARV4IDUs (Antiretrovirals for Injecting Drug Users) and non-techical treatment guides on starting and changing treatment, side effects, hepatitis C coinfection and HIV and pregnancy.

i-Base is involved in several community networks, including the UK Community Advisory Board (UK-CAB), the European AIDS Treatment Group (EATG), the European Community Advisory Board (ECAB) and the International Treatment Preparedness Coalition (ITPC) and the AIDS Treatment Activists Coalition (ATAC).

We have also developed close working relationships with NGOs in many different countries in Western and Eastern Europe and Africa. Copyright free i-Base material has been produced in over 40 languages.

We are directly involved in research with INSIGHT network, PENTA network, MRC studies in the UK, Metabolic Oversight Committee and D:A:D studies.

Treatment guides and i-Base authored articles in HTB may be reproduced by NHS, community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original source on the i-Base Web site is always appreciated. All i-Base material remains the copyright of HIV i-Base.

HIV i-Base receives unconditional educational grants from charitable trusts, individual donors and pharmaceutical companies. All editorial policies are strictly independent of funding sources.

HIV i-Base is a registered charity no.1081905 and company limited by guarantee no. 3962064.

How to Reach HIV i-Base

4rd Floor
57a Great Suffolk Street

Phone: +44 (0) 20 7407 8488
Treatment phoneline: 0808 800 6013, Mon., Tues., Wed. 12-4 pm
Fax: +44 (0) 20 7407 8489

Categories Covered:Darunavir (Prezista), Pregnancy, Childbirth, and HIV, Adverse Events, Comorbidities, and HIV, HIV Care and Services Outside the US, Tenofovir Disoproxil Fumarate (Viread), Lopinavir/Ritonavir (Kaletra), Rilpivirine (Edurant), Etravirine (Intelence), Raltegravir (Isentress), HIV Treatment Strategies, HIV Treatments in Development, Conceiving and Having a Baby, Women, PrEP (HIV Pre-Exposure Prophylaxis), HIV Epidemiology, First-Line HIV Treatment, Providing Quality HIV Care, Maraviroc (Selzentry, Celsentri), Living Well With HIV, Zidovudine (AZT, Retrovir), HIV Testing, FDA-Approved HIV Medications, Efavirenz (Sustiva, Stocrin), HIV Prevention Methods, Cobicistat/Darunavir (Prezcobix), HIV Case Management and Social Work, Atazanavir (Reyataz), Stavudine (d4T, Zerit), Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla), Managing HIV Drug Resistance, Pediatric HIV Care, Managing Long-Term HIV Survivors, Nelfinavir (Viracept), Saquinavir (Invirase), Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Physical Health Issues, HIV Education and Risk Management, HIV, Discrimination, and Law, Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi Lo), Meeting the Costs of HIV Care, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Managing Primary/Acute HIV Infection, HIV Policy and Advocacy, HIV Basic Science and Pathogenesis, Managing People Newly Diagnosed With HIV, HIV Care Continuum, Zerit (Stavudine, d4T), HIV in Specific Countries, Nevirapine (Viramune), Dolutegravir (Tivicay), Abacavir (Ziagen), HIV Testing, Non-Medical HIV Prevention, HIV Advocates in the Spotlight, HIV in Film, TV, and Media, HIV Prevention and Transmission, HIV Treatment and Medical Care, Newly Diagnosed, Didanosine (ddI, Videx), Elvitegravir (Vitekta), PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention for People With HIV, HIV Advocacy and Activism, Financial Issues, Starting HIV Treatment and Medical Care, PEP (HIV Post-Exposure Prophylaxis), Abacavir/Lamivudine (Epzicom, Kivexa), Body Fat, Lipodystrophy and HIV, Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF), Cobicistat (Tybost), Atazanavir/Cobicistat (Evotaz), Non-HIV Sexually Transmitted Infections, Ritonavir (Norvir), Lamivudine/Zidovudine (Combivir), Lamivudine (3TC, Epivir), Fosamprenavir (Lexiva, Telzir), Switching or Stopping HIV Treatment, Understanding HIV-Related Lab Tests, Switching or Stopping HIV Treatment, Enfuvirtide (T-20, Fuzeon), HIV in Books and Publishing, HIV and Mental Health Care

Latest by HIV i-Base

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study

The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.

By Simon Collins for HIV i-Base

Viral Reservoir Can Explain Persistent Low Level Viremia With Good Adherence on ART

A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.

By Simon Collins for HIV i-Base

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

By Simon Collins for HIV i-Base

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

By Polly Clayden for HIV i-Base

NHS England Doubles Places on IMPACT PrEP Study to 26,000

Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.

By Simon Collins for HIV i-Base

FDA Approves Generic TDF/3TC for Use in the U.S.

The U.S. FDA has approved Temixys, a generic combination tablet of tenofovir disoproxil fumarate plus lamivudine.

By Simon Collins for HIV i-Base

Why U=U Does Not Cover Breastfeeding

"Undetectable equal untransmittable" is sometimes wrongly interpreted as covering all ways that HIV can be transmitted.

By Simon Collins for HIV i-Base

How to Evaluate PrEP and Vaccines: Urgency for Next-Generation Compounds

Several presentations at the 2018 HIV Research for Prevention conference looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

By Simon Collins for HIV i-Base

HIV Diagnoses in UK Drop for Third Year: Among All Ages, Risk Groups, and Ethnicities and Across Most UK Regions

Preliminary data released by Public Health England show that HIV diagnoses dropped by 17% in 2017 compared to 2016.

By Simon Collins for HIV i-Base